Literature DB >> 27161939

The STHLM3 prostate cancer diagnostic study: calibration, clarification, and comments.

Martin Eklund1, Henrik Grönberg1, Tobias Nordström1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27161939     DOI： 10.1038/nrclinonc.2016.80

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  Prostate cancer: Personalized risk - stratified screening or abandoning it altogether?

Authors:  Sigrid V Carlsson; Michael W Kattan
Journal:  Nat Rev Clin Oncol       Date:  2016-02-02       Impact factor: 66.675

2.  Testing for improvement in prediction model performance.

Authors:  Margaret Sullivan Pepe; Kathleen F Kerr; Gary Longton; Zheyu Wang
Journal:  Stat Med       Date:  2013-01-07       Impact factor: 2.373

3.  A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

Authors:  William J Catalona; Alan W Partin; Martin G Sanda; John T Wei; George G Klee; Chris H Bangma; Kevin M Slawin; Leonard S Marks; Stacy Loeb; Dennis L Broyles; Sanghyuk S Shin; Amabelle B Cruz; Daniel W Chan; Lori J Sokoll; William L Roberts; Ron H N van Schaik; Isaac A Mizrahi
Journal:  J Urol       Date:  2011-03-17       Impact factor: 7.450

4.  Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer.

Authors:  Sanoj Punnen; Nicola Pavan; Dipen J Parekh
Journal:  Rev Urol       Date:  2015

5.  The prostate health index selectively identifies clinically significant prostate cancer.

Authors:  Stacy Loeb; Martin G Sanda; Dennis L Broyles; Sanghyuk S Shin; Chris H Bangma; John T Wei; Alan W Partin; George G Klee; Kevin M Slawin; Leonard S Marks; Ron H N van Schaik; Daniel W Chan; Lori J Sokoll; Amabelle B Cruz; Isaac A Mizrahi; William J Catalona
Journal:  J Urol       Date:  2014-11-15       Impact factor: 7.450

6.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen
Journal:  Lancet       Date:  2014-08-06       Impact factor: 79.321

7.  Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.

Authors:  Henrik Grönberg; Jan Adolfsson; Markus Aly; Tobias Nordström; Peter Wiklund; Yvonne Brandberg; James Thompson; Fredrik Wiklund; Johan Lindberg; Mark Clements; Lars Egevad; Martin Eklund
Journal:  Lancet Oncol       Date:  2015-11-10       Impact factor: 41.316

8.  Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.

Authors:  Richard J Bryant; Daniel D Sjoberg; Andrew J Vickers; Mary C Robinson; Rajeev Kumar; Luke Marsden; Michael Davis; Peter T Scardino; Jenny Donovan; David E Neal; Hans Lilja; Freddie C Hamdy
Journal:  J Natl Cancer Inst       Date:  2015-04-11       Impact factor: 13.506
  8 in total
  2 in total

1.  The STHLM3 prostate cancer diagnostic study: calibration, clarification, and comments.

Authors:  Sigrid V Carlsson; Michael W Kattan
Journal:  Nat Rev Clin Oncol       Date:  2016-05-10       Impact factor: 66.675

Review 2.  Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017.

Authors:  Sigrid V Carlsson; Monique J Roobol
Journal:  Curr Opin Urol       Date:  2017-05       Impact factor: 2.309
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.